A double-blind trial with baclofen (Lioresal) and diazepam in spasticity due to multiple sclerosis.
In 17 in-patients suffering from spasticity due to multiple sclerosis, the effect and tolerability periods were 4 weeks each. As to efficacy, the variables: spasticity, clonus, flexor spasms, gait and bladder function were evaluated clinically. No significant difference was found between the two drugs. As far as side-effects are concerned, sedation was specifically inquired about. Apart from that, spontaneoulsy reported side-effects were recorded. Sedation was more often seen during treatment with diazepam, while the side-effects during baclofen treatment were more varied. The total number and severity of side-effects were equal in the two treatment groups. A preference for one of the two treatment periods was stated by the investigator before the code was broken. A significant difference (p less than 0.001) in favor of Lioresal was found. This is discussed in the light of the fact that no significant difference was found for the individual symptoms or side-effects.
D000328:Adult; D000368:Aged; D000613:Aminobutyrates / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002722:Chlorobenzenes / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003975:Diazepam / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D005684:Gait; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy*; D009119:Muscle Contraction / Q000187:drug effects; D009127:Muscle Rigidity / Q000188:drug therapy; D010919:Placebos; D013035:Spasm / Q000188:drug therapy*; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy; D014549:Urinary Incontinence / Q000188:drug therapy
D000613:Aminobutyrates; D002722:Chlorobenzenes; D010919:Placebos; D003975:Diazepam